{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '2.1', 'Schedule of Assessments', 'Treatment Period 2', 'Follow-Up', 'Screening\u00b9', 'Follow-Up Period 3', 'Contact4', '11/', '16/', 'Study Visit', 'S1/S2/S3', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '12', '13', '14', '15', 'PW154', 'PW2 6\u00ea', '17', '18', 'Week (W)/', '-42 to-14', 'Day 126', 'W1', 'W3', 'W4/', 'W6', 'W9', 'W12/', 'W15', 'W18', 'W21', 'W24/', 'W28/', 'W36/', 'W48/', 'W60/', 'W72/', 'W96/', 'W120/', 'Month (M)', 'days', 'M1', 'M3', 'M6', 'M7', 'M9', 'M12', 'M15', 'M18', 'M42', 'M66', 'Visit Window ( days)', '(+3)', '(+1)', '(=3)', '(+1)', '(+3)', '(=3)', '(+3)', '(+3)', '(=3)', '(+3)', '(=7)', '(+7)', '(+7)', '(+7)', '(+7)', '(+7)', '(14)', '(14)', 'Informed Consent', 'X', 'Review inc/exc criteria', 'X', 'Demographics', 'X', 'Medical History 87', 'X28', 'X', 'Weight 109', 'X', 'X', 'X', 'X', 'X', 'Randomization 110', 'X26', 'Study drug infusion', 'Phone (email) contact for safety', 'x', '24 hours postdose', 'Efficacy assessments', 'CAS 132', 'X', 'X14', 'X', 'X', 'X', 'X', 'Clinical Measures of Severity', '- includes proptosis, diplopia', 'X', 'X154', 'X', 'X', 'X', 'and motility restriction', 'Safety assessments', 'Pregnancy Test', 'X', 'X', 'X', 'Physical exam 187', 'X 198', 'X187', 'X18\u00b2', 'X', '187', 'Ophthalmic exam 2019', '720', 'X', 'X', 'X', 'Vital Signs 224', 'X', 'X22+', 'X', 'X', '12-Lead ECG', 'X', 'X', 'X', 'Clinical laboratory tests 232', 'Chemistry (excl. glucose)', 'X', 'X', 'X', 'Thyroid (FT3, FT4, TSH)', '25-', 'X', 'X', 'X', 'X', 'X', 'Hematology', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 10 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'Follow-Up', 'Screening 1', 'Treatment Period 2', 'Follow-Up Period\u00b3', 'Contact4', '11/', '16/', 'Study Visit', 'S1/S2/S3', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '12', '13', '14', '15', 'PW154', 'PW2 65', '17', '18', 'Week (W)/', '-42 to -14', 'Day 1 26', 'W1', 'W3', 'W4/', 'W6', 'W9', 'W12/', 'W15', 'W18', 'W21', 'W24/', 'W28/', 'W36/', 'W48/', 'W60/', 'W72/', 'W96/', 'W120/', 'Month (M)', 'days', 'M1', 'M3', 'M6', 'M7', 'M9', 'M12', 'M15', 'M18', 'M42', 'M66', 'Visit Window ( days)', '(+3)', '(+1)', '(+3)', '(+1)', '(+3)', '(+3)', '(+3)', '(+3)', '(+3)', '(+3)', '(+7)', '(=7)', '(+7)', '(+7)', '(+7)', '(+7)', '(+14)', '(+14)', 'Glucose', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'HbAlc', 'X', 'X', 'X', 'X', 'Urinalysis', 'X', 'X', 'X', 'X', 'X', 'ADA/NAb samples 276', 'X', 'X', '2830', 'X', 'X', 'AE, SAE assessment 297', 'X', 'X', 'X', 'X', 'X', 'X', 'Concomitant medications', 'X', 'GO-QoL Questionnaire', 'X', 'X', 'Biomarker samples 3028', 'PK samples 3129', 'Contact (phone/email) to', 'assess additional TED', 'treatment 32', 'ADA=anti-drug antibody; AE=adverse event; CAS=Clinical Activity Score; ECG=electrocardiogram; FT3=free triiodothyronine; FT4=free thyroxine;', 'FU=Follow-Up;', \"GO-QoL=Graves' Ophthalmopathy Quality of Life Questionnaire; HbAlc=glycated hemoglobin; M=month; NAb=neutralizing antibody; PK=pharmacokinetic; PW=premature\", 'withdrawal; SAE=serious adverse event; TED=thyroid eye disease; TSH=thyroid stimulating hormone; W=week.', 'Footnotes:', '1.', 'Screening procedures can take place over more than 1 day/clinic visit provided consent is obtained first and all assessments are completed within the designated window.', '2.', 'Double-masked Treatment Period. Subjects who are proptosis non-responders at Week 24 are eligible to enroll in an open-label extension study in which all subjects will', 'receive teprotumumab 20 mg/kg (10 mg/kg for the first infusion and 20 mg/kg for the remaining infusions).', '3.', 'Proptosis responders and non-responders who choose not to enroll in the open-label extension study will participate in a 48-week Follow-Up Period.', '4.', 'Subjects who complete the Week 72 Visit will be contacted via phone or email by research staff to enquire if any treatment for TED has been received since last', 'study contact.', '5.4.', 'If a subject prematurely discontinues study drug during the Treatment Period, they will return for a clinic visit and undergo the Week 24 assessments, with the exception of', 'the collection of blood samples for PK and ADA evaluations. Subjects will be encouraged to continue study participation in the Follow-Up Period.', '6.5.', 'If a subject prematurely discontinues from the study during the Follow-Up Period, they will return for a clinic visit and undergo the Week 72 assessments prior to', 'discharge.', '7.6.', 'On Day 1 (Baseline), subjects will be randomized and receive the first dose of study drug; however, Baseline assessments will be performed prior to dosing.', '8.7.', \"Medical history including tobacco use history and Graves' disease and treatment history.\", 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 11 of 117']\n\n###\n\n", "completion": "END"}